Letting people know that I see them as more than just their diagnosis helps to build trust. The woman who nominated me is a patient I see every month, and I’ve gotten to know her really well. She has four sons — two in college and one who got married recently — so she certainly has a lot going on!
Because of AML’s aggressive nature, it traditionally requires aggressive—and immediate—treatment that involves intensive, high-dose chemotherapy and many weeks in the hospital. For older patients, however, such grueling treatment isn’t always promising, and many are mistakenly advised that their time and options are limited.
Four weeks after her 33rd birthday, Crystal found a lump in her breast. When she told a good friend and co-worker — whose mother happened to be in treatment for metastatic breast cancer — the friend told her, “Don’t mess around.”
Borderline ovarian tumors represent a small subset of epithelial ovarian tumors. Because it’s an uncommon and unfamiliar diagnosis, it’s often misunderstood.
“Initially, ovarian cancer, melanoma, and some sarcomas are the three main targets,” says Dr. Koya, “but the clinical trial is open for patients with other cancers who meet the eligibility requirements."
My son, David, was 13 years old when he was diagnosed with acute lymphoblastic leukemia (ALL). My husband and I are both medical professionals, and cancer never entered our minds when David exhibited signs of fatigue, sore throat and listlessness.
Collected last week from a patient with late-stage ovarian cancer, these are not ordinary T cells; they have been altered and multiplied in the hope that when they are given back to her, they will launch a devastating attack on her cancer cells.